These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

565 related articles for article (PubMed ID: 35839443)

  • 21. Circulating Tumor DNA: Towards More Individualized Treatment for Patients with Resectable Colorectal Cancer.
    Adams AM; Vreeland TJ; Newhook TE
    J Gastrointest Cancer; 2023 Dec; 54(4):1071-1081. PubMed ID: 36562938
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liquid biopsy in colorectal cancer: Onward and upward.
    Torresan S; de Scordilli M; Bortolot M; Di Nardo P; Foltran L; Fumagalli A; Guardascione M; Ongaro E; Puglisi F
    Crit Rev Oncol Hematol; 2024 Feb; 194():104242. PubMed ID: 38128627
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients.
    Petrillo A; Salati M; Trapani D; Ghidini M
    Curr Drug Targets; 2021; 22(9):1010-1020. PubMed ID: 33155906
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Longitudinal ctDNA profiling in precision oncology and immunο-oncology.
    Filis P; Kyrochristos I; Korakaki E; Baltagiannis EG; Thanos D; Roukos DH
    Drug Discov Today; 2023 Apr; 28(4):103540. PubMed ID: 36822363
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CIRCULATE-Japan: Circulating tumor DNA-guided adaptive platform trials to refine adjuvant therapy for colorectal cancer.
    Taniguchi H; Nakamura Y; Kotani D; Yukami H; Mishima S; Sawada K; Shirasu H; Ebi H; Yamanaka T; Aleshin A; Billings PR; Rabinowitz M; Oki E; Takemasa I; Kato T; Mori M; Yoshino T
    Cancer Sci; 2021 Jul; 112(7):2915-2920. PubMed ID: 33931919
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Personalised circulating tumour DNA assay with large-scale mutation coverage for sensitive minimal residual disease detection in colorectal cancer.
    Ryoo SB; Heo S; Lim Y; Lee W; Cho SH; Ahn J; Kang JK; Kim SY; Kim HP; Bang D; Kang SB; Yu CS; Oh ST; Park JW; Jeong SY; Kim YJ; Park KJ; Han SW; Kim TY
    Br J Cancer; 2023 Aug; 129(2):374-381. PubMed ID: 37280413
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Research progress on circulating tumor DNA as a biomarker for minimal residual disease in solid tumors].
    Chen Y
    Zhongguo Dang Dai Er Ke Za Zhi; 2023 Oct; 25(10):1072-1077. PubMed ID: 37905766
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Detection of Molecular Residual Disease Using Personalized Circulating Tumor DNA Assay in Patients With Colorectal Cancer Undergoing Resection of Metastases.
    Loupakis F; Sharma S; Derouazi M; Murgioni S; Biason P; Rizzato MD; Rasola C; Renner D; Shchegrova S; Koyen Malashevich A; Malhotra M; Sethi H; Zimmermann BG; Aleshin A; Moshkevich S; Billings PR; Sedgwick JD; Schirripa M; Munari G; Cillo U; Pilati P; Dei Tos AP; Zagonel V; Lonardi S; Fassan M
    JCO Precis Oncol; 2021 Jul; 5():. PubMed ID: 34327297
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Liquid biopsy in colorectal cancer : An overview of ctDNA analysis in tumour diagnostics].
    Haupts A; Roth W; Hartmann N
    Pathologe; 2019 Dec; 40(Suppl 3):244-251. PubMed ID: 31797045
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development and validation of postoperative circulating tumor DNA combined with clinicopathological risk factors for recurrence prediction in patients with stage I-III colorectal cancer.
    Gao Z; Huang D; Chen H; Yang Y; An K; Ding C; Yuan Z; Zhai Z; Niu P; Gao Q; Cai J; Zeng Q; Wang Y; Hong Y; Rong W; Huang W; Lei F; Wang X; Chen S; Zhao X; Bai Y; Gu J
    J Transl Med; 2023 Jan; 21(1):63. PubMed ID: 36717891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating tumor DNA is a prognostic marker of tumor recurrence in stage II and III colorectal cancer: multicentric, prospective cohort study (ALGECOLS).
    Benhaim L; Bouché O; Normand C; Didelot A; Mulot C; Le Corre D; Garrigou S; Djadi-Prat J; Wang-Renault SF; Perez-Toralla K; Pekin D; Poulet G; Landi B; Taieb J; Selvy M; Emile JF; Lecomte T; Blons H; Chatellier G; Link DR; Taly V; Laurent-Puig P
    Eur J Cancer; 2021 Dec; 159():24-33. PubMed ID: 34731746
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Relationship between post-surgery detection of methylated circulating tumor DNA with risk of residual disease and recurrence-free survival.
    Murray DH; Symonds EL; Young GP; Byrne S; Rabbitt P; Roy A; Cornthwaite K; Karapetis CS; Pedersen SK
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1741-1750. PubMed ID: 29992492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circulating tumour DNA as a biomarker in resectable and irresectable stage IV colorectal cancer; a systematic review and meta-analysis.
    Jones RP; Pugh SA; Graham J; Primrose JN; Barriuso J
    Eur J Cancer; 2021 Feb; 144():368-381. PubMed ID: 33422803
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deep sequencing of circulating tumor DNA detects molecular residual disease and predicts recurrence in gastric cancer.
    Yang J; Gong Y; Lam VK; Shi Y; Guan Y; Zhang Y; Ji L; Chen Y; Zhao Y; Qian F; Chen J; Li P; Zhang F; Wang J; Zhang X; Yang L; Kopetz S; Futreal PA; Zhang J; Yi X; Xia X; Yu P
    Cell Death Dis; 2020 May; 11(5):346. PubMed ID: 32393783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Circulating tumor DNA guided adjuvant chemotherapy in stage II colon cancer (MEDOCC-CrEATE): study protocol for a trial within a cohort study.
    Schraa SJ; van Rooijen KL; van der Kruijssen DEW; Rubio Alarcón C; Phallen J; Sausen M; Simmons J; Coupé VMH; van Grevenstein WMU; Elias S; Verkooijen HM; Laclé MM; Bosch LJW; van den Broek D; Meijer GA; Velculescu VE; Fijneman RJA; Vink GR; Koopman M;
    BMC Cancer; 2020 Aug; 20(1):790. PubMed ID: 32819390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications.
    Croessmann S; Park BH
    Clin Adv Hematol Oncol; 2021 Mar; 19(3):155-161. PubMed ID: 33739964
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BESPOKE study protocol: a multicentre, prospective observational study to evaluate the impact of circulating tumour DNA guided therapy on patients with colorectal cancer.
    Kasi PM; Sawyer S; Guilford J; Munro M; Ellers S; Wulff J; Hook N; Krinshpun S; Koyen Malashevich A; Malhotra M; Rodriguez A; Moshkevich S; Grothey A; Kopetz S; Billings P; Aleshin A
    BMJ Open; 2021 Sep; 11(9):e047831. PubMed ID: 34561256
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical application of circulating tumour DNA in colorectal cancer.
    Loft M; To YH; Gibbs P; Tie J
    Lancet Gastroenterol Hepatol; 2023 Sep; 8(9):837-852. PubMed ID: 37499673
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of postsurgery circulating tumor DNA in nonmetastatic colorectal cancer: Individual patient pooled analysis of three cohort studies.
    Tie J; Cohen JD; Lo SN; Wang Y; Li L; Christie M; Lee M; Wong R; Kosmider S; Skinner I; Wong HL; Lee B; Burge ME; Yip D; Karapetis CS; Price TJ; Tebbutt NC; Haydon AM; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Popoli M; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Int J Cancer; 2021 Feb; 148(4):1014-1026. PubMed ID: 32984952
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Implications of Monitoring Circulating Tumor DNA in Patients with Colorectal Cancer.
    Schøler LV; Reinert T; Ørntoft MW; Kassentoft CG; Árnadóttir SS; Vang S; Nordentoft I; Knudsen M; Lamy P; Andreasen D; Mortensen FV; Knudsen AR; Stribolt K; Sivesgaard K; Mouritzen P; Nielsen HJ; Laurberg S; Ørntoft TF; Andersen CL
    Clin Cancer Res; 2017 Sep; 23(18):5437-5445. PubMed ID: 28600478
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.